Abstract Library

#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Alors-Pérez E

Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,

Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,

#2006 The Frequency of Patients with Giant Pituitary Tumors from Retrospective Data

Introduction: In this scientific article an author discusses the results of researches 121 patients with different by volume formations of sellar area, from them - men - 59 (48,9%), women - 62 (51,1%).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Urmanova Y

Authors: Urmanova Y, Rikhsieva N, Khodgaeva F, Tursunkulov O,

Keywords: giant pituitary adenomas,

#1838 A Rare Case of Ectopic Cushing's Syndrome

Introduction: Cushing's syndrome has an incidence of 0.7 - 2.4 per million people per year. In 15% of cases, it’s associated with non-pituitary tumors secreting ACTH. Pheochromocytoma accounts for 5% of ectopic ACTH secretion.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Steina L

Authors: Steina L, Steina S, Pirags V, Ozolins A, Gardovskis J,

Keywords: malignant pheochromocytoma,

#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience

Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Glaser B, Barak D, Fraenkel M, Gross D,

Keywords: MEN-1, hyperparathyroidism, pituitary tumors, gastroenteropancreatic tumors, menin,

#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy

Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Gross D, Doviner V, Dresner-Pollak R,

Keywords: pituitary carcinoma, peptide receptor radionuclide therapy, acromegaly,